We designed another use case to validate PAS for gene‐variants (Figure 5), which include somatic mutations (hallmark for cancer) related to eight different reported genes: estrogen receptor 1 gene (ESR1),128 AKT serine/threonine kinase 1 gene (AKT1),129 Erb‐B2 receptor tyrosine kinase 2 gene (ERBB2), breast cancer type 1 susceptibility protein gene (BRCA1),5 breast cancer type 2 susceptibility protein gene (BRCA2),5 RNA binding motif protein 10 gene (RBM10),99 protein tyrosine phosphatase nonreceptor type 13 gene (PTPN13), and protein phosphatase 6 catalytic subunit gene (PPP6C).93 This evidence concerns the gene ERBB2 and cancer.